<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615444</url>
  </required_header>
  <id_info>
    <org_study_id>QueenMUsz</org_study_id>
    <nct_id>NCT02615444</nct_id>
  </id_info>
  <brief_title>The Effects of Beta-glucan Enriched Oatcake Consumption on Metabolic Disease Risk Factors</brief_title>
  <official_title>An Investigation of the Effects of Consuming Oatcakes Containing 4g of Oat Beta-glucan on Physiological Parameters in Individuals at Risk of Developing Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Margaret University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Margaret University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether daily consumption of soluble fibre, oat
      beta glucan (4g), for six weeks will have any impact on overweight/obese individuals in terms
      of risk factors used to define metabolic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether daily consumption oat beta glucan (4g) for
      six weeks will have any impact on overweight/obese individuals in terms of risk factors used
      to define metabolic disease.

      Oat beta-glucan has been incorporated into a novel oatcake product manufactured by Nairn's
      Oatcakes Ltd. Consumption of the oatcake products will deliver enough oat-beta glucan to the
      diet to meet European Food Safety Authority health claims for lowering blood cholesterol and
      reducing post-prandial glycaemic responses.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Triglycerides</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum HDL Cholesterol</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum total Cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy Intakes (kilocalories) and Macronutrient intakes (grams) from food diaries</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Beta-glucan enriched oatcake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocaloric control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-glucan enriched oatcake</intervention_name>
    <description>5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks</description>
    <arm_group_label>Beta-glucan enriched oatcake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isocaloric control</intervention_name>
    <description>6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks</description>
    <arm_group_label>Isocaloric control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 years and older

          -  Waist circumference measurements of ≥94cm for males and 80cm for females, or a body
             mass index of ≥30kg/m2

          -  Individuals who are able to provide informed consent

        Exclusion Criteria:

          -  Postmenopausal females

          -  Smokers

          -  Individuals who suffer from, or taking medication for, cardiovascular or
             gastro-intestinal disease

          -  Impaired glucose tolerance/Diabetes mellitus

          -  Pregnancy or breastfeeding

          -  Those who have high dietary fibre intakes (&gt;20g/day)

          -  Known food allergies to oats, wheat, lactose, or sesame seeds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Zaremba</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Margaret University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Margaret University, Edinburgh</name>
      <address>
        <city>Musselburgh</city>
        <state>East Lothain</state>
        <zip>EH21 6UU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Pouliot MC, Després JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994 Mar 1;73(7):460-8.</citation>
    <PMID>8141087</PMID>
  </reference>
  <reference>
    <citation>Lissner L, Lindroos AK, Sjöström L. Swedish obese subjects (SOS): an obesity intervention study with a nutritional perspective. Eur J Clin Nutr. 1998 May;52(5):316-22. Review.</citation>
    <PMID>9630380</PMID>
  </reference>
  <reference>
    <citation>Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev. 2001 May;59(5):129-39. Review.</citation>
    <PMID>11396693</PMID>
  </reference>
  <reference>
    <citation>Liatis S, Tsapogas P, Chala E, Dimosthenopoulos C, Kyriakopoulos K, Kapantais E, Katsilambros N. The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes. Diabetes Metab. 2009 Apr;35(2):115-20. doi: 10.1016/j.diabet.2008.09.004. Epub 2009 Feb 20.</citation>
    <PMID>19230737</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Margaret University</investigator_affiliation>
    <investigator_full_name>Suzanne Zaremba</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Overweight</keyword>
  <keyword>Waist Circumference</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Oat beta glucan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

